Placenta extract injection aims to tame chronic liver disease

NCT ID NCT06493799

Recruiting now Disease control Sponsor: Green Cross Wellbeing Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a drug called LAENNEC, made from human placenta, in people with chronic liver disease. It compares giving the drug as an intravenous drip versus a standard shot under the skin. The main goal is to see if the IV form lowers liver enzyme levels more effectively over 6 weeks. About 226 adults with alcoholic or non-alcoholic fatty liver disease and elevated ALT levels are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LAENNEC (human placenta hydrolysate)
What this could lead to: If successful, this could offer a new way to deliver LAENNEC intravenously to better manage chronic liver disease and reduce liver enzyme levels.
What could go wrong: This is a Phase 3 trial, but it compares two forms of the same drug, not against a placebo. The benefit over standard care is unclear, and long-term outcomes are not measured.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOLIC FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcoholic fatty liver disease liver disorder metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LIVER DISEASE

Contacts and locations

Locations

GC wellbeing
RECRUITING

Yongin-si, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.